Martin Bonde

Martin Bonde is CEO of Danish oncology company Akylox Therapeutics Aps. With 30+ years of experience from the biotech industry, Martin has held several leadership positions as CEO for example Inthera BioScience AG, Vaccibody AS (now Nykode Therapeutics AS, Euronext Growth Oslo:VACC), Epitherapeutics Aps (sold to Gilead Sciences, Inc.), NatImmune A/S (sold to Azanta A/S), Combio A/S (sold to Arpida AG), Torsana Biosensor (sold to Celtor Bioscience, Inc.), and Osteometer Biotech (now Nordic Bioscience A/S). Martin currently serves as Chairman of the Board in private Swedish oncology company Asgard Therapeutics AB and as Chairman of the Board of Directors in private German liver regeneration company Heparegenix GmbH. Moreover, he serves on the board of Directors in privately held Danish digital pathology software company Visiopharm A/S, in Swiss oncology company Inthera Bioscience AG and in BioInnovation Institute (BII), an international life science incubator funded by the Novo-Nordisk Foundation. Martin holds a Master of Science and Ph.D in Chemical Engineering from the Technical University of Denmark as well as a Graduate Diploma in Business Administration (HD i Udenrigshandel) from Copenhagen Business School.